Editas Medicine Announces Positive Safety And Efficacy Data From Sickle Cell Disease Patients Treated In The RUBY Trial Of EDIT-301

Published on December 06, 2022 03:36 AM PST

Editas Medicine Announces Positive Safety And Efficacy Data From Sickle Cell Disease Patients Treated In The RUBY Trial Of EDIT-301 — Image source: ©2022 Kalkine Media®

Dec 6 (Reuters) - Editas Medicine Inc:

* EDITAS MEDICINE ANNOUNCES POSITIVE SAFETY AND EFFICACY DATA FROM THE FIRST TWO PATIENTS TREATED IN THE RUBY TRIAL OF EDIT-301 FOR THE TREATMENT OF SEVERE SICKLE CELL DISEASE

* EDITAS MEDICINE INC - EDIT-301 WAS WELL-TOLERATED AND DEMONSTRATED A SAFETY PROFILE

* EDITAS MEDICINE INC - BOTH PATIENTS TREATED WITH EDIT-301 SUCCESSFULLY ENGRAFTED AND ARE FREE OF VASO-OCCLUSIVE EVENTS DURING FOLLOW-UP PERIOD

* EDITAS MEDICINE - FIRST PATIENT TREATED HAS A TOTAL HEMOGLOBIN LEVEL OF 16.4 G/DL AND 45.4% FETAL HEMOGLOBIN FIVE MONTHS AFTER TREATMENT WITH EDIT-301 Source text for Eikon: Further company coverage:

Reuters

Reuters -
93960 Posts
...

Disclaimer

The above content is directly sourced from Reuters under a contractual arrangement. The content is being provided as a convenience and for informational purposes only; and does not constitute an endorsement or approval by Kalkine Media of any of the products, services, or opinions of the organization or individual. The user is apprised that Kalkine Media bears no responsibility for the accuracy, legality, or content of Reuters, any external sites, or for that of subsequent links. The user is requested to contact Reuters directly for answers to questions regarding the content. Please note that Kalkine Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.